Inozyme Pharma
Clinical trials sponsored by Inozyme Pharma, explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- Can a replacement enzyme keep calcium buildup in check? Results expected Oct 2026 (estimated)
- New hope for babies with rare calcification disease: first drug trial launches Results expected Oct 2026 (estimated)
- New hope for babies: drug targets rare genetic disorder that hardens arteries Results expected Oct 2026 (estimated)
-
Can a protein boost help heal blood vessel damage in dialysis patients?
Disease control CompletedThis early-stage trial is testing an experimental drug called INZ-701 in adults with end-stage kidney disease who are on hemodialysis and have low levels of a natural substance called pyrophosphate, which helps prevent calcium buildup in blood vessels. The study aims to see if we…
Phase 1 • Sponsor: Inozyme Pharma • Aim: Disease control
Last updated Aug 26, 2026 00:00 UTC
-
Can medical records unlock the secrets of rare calcification diseases?
Knowledge-focused CompletedThis study looks back at medical records of people with two rare genetic conditions—ENPP1 deficiency and the early-onset form of ABCC6 deficiency—to map how these diseases progress over time. By collecting information on symptoms, imaging, and growth, researchers hope to better u…
Sponsor: Inozyme Pharma • Aim: Knowledge-focused
Last updated Aug 06, 2026 00:00 UTC
-
Rare disease detectives: new study maps how two genetic conditions unfold in children
Knowledge-focused CompletedThis study follows children aged 2 to 18 with confirmed ENPP1 deficiency or early-onset ABCC6 deficiency to understand how these rare diseases progress. Researchers will measure blood markers, check for calcification in arteries and organs, and track bone health and movement over…
Sponsor: Inozyme Pharma • Aim: Knowledge-focused
Last updated Jul 08, 2026 00:00 UTC